Fimasartan on Hypertensive Cardiac Disease With Left Ventricular Hypertrophy Estimated by ECG

NCT03219632 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 72

Last updated 2017-07-17

No results posted yet for this study

Summary

Assess the efficacy of fimasartan on left ventricular hypertrophy in hypertensive patients

Conditions

Interventions

DRUG

Fimasartan

Fimasartan is a non-peptide angiotensin II receptor antagonist (ARB) used for the treatment of hypertension and heart failure.

Sponsors & Collaborators

  • Seoul National University Bundang Hospital

    lead OTHER

Principal Investigators

  • Dong-Ju choi · Seoul National University Bundang Hospital

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-05
Primary Completion
2017-04-30
Completion
2017-05-30

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03219632 on ClinicalTrials.gov